About Richard Knight

Dr Richard Knight PhD, ERT. A co-founder of ApconiX, Richard is an expert toxicologist with more than 20 years of drug development experience gained in AstraZeneca, where he was part of the Drug Safety and Oncology Leadership Teams. Richard has worked on projects in multiple therapy areas involving small molecules, biologics, proteins and oligonucleotides. He has an in-depth understanding of drug discovery and drug development and has been directly involved in bringing over 35 new candidate drugs to clinical trials and 6 to marketing approval. He uses his extensive experience to bring an innovative, science-led and pragmatic approach to the design and delivery of nonclinical safety programmes.

ApconiX Welcomes Sarah Pass

ApconiX Welcomes Sarah Pass ApconiX is delighted to welcome Sarah Pass who joins the team of nonclinical DMPK experts and will be working with Dr Richard Knight.  With a career in both industry and contract research, Sarah is an experienced drug metabolism and pharmacokinetics (DMPK) scientist with experience of [...]

By |2022-12-06T13:17:57+00:00December 6th, 2022|Company News, Toxicology, Careers|Comments Off on ApconiX Welcomes Sarah Pass

Lean Life Science and Cancer Research UK Launch the Oncology Development Programme (ODP2) to Accelerate Development of High Impact Novel Cancer Innovations

Lean Life Science and Cancer Research UK Launch the Oncology Development Programme (ODP2) to Accelerate Development of High Impact Novel Cancer Innovations ApconiX is very excited to be part of Oncology Development Programme2 (ODP2) the latest Development Programme launched on the 21st of November at Alderley Park focused on [...]

By |2022-11-29T09:22:45+00:00November 28th, 2022|Company News|Comments Off on Lean Life Science and Cancer Research UK Launch the Oncology Development Programme (ODP2) to Accelerate Development of High Impact Novel Cancer Innovations

ApconiX Welcomes Dr Amy Shepherd

ApconiX Welcomes Dr Amy Shepherd ApconiX is delighted to welcome Dr Amy Shepherd who joins the team of nonclinical safety experts and will be working with Dr Richard Knight. Amy is an experienced immunologist having worked for over 10 years in nonclinical and clinical safety program design with both [...]

By |2022-11-22T13:01:59+00:00October 8th, 2022|Company News, Toxicology, Careers|Comments Off on ApconiX Welcomes Dr Amy Shepherd

ApconiX Welcomes Scott Hackford

ApconiX Welcomes Scott Hackford ApconiX is delighted to welcome Scott Hackford who joins the team of nonclinical safety experts and will be working with Dr Richard Knight. Scott has over 12 years’ experience in a contract research organisation as a study director and lead toxicologist designing, conducting, and reporting [...]

By |2022-11-22T13:06:52+00:00October 1st, 2022|Company News, Toxicology, Careers|Comments Off on ApconiX Welcomes Scott Hackford

ApconiX Welcomes Dr Kerry Illston

ApconiX Welcomes Dr Kerry Illston ApconiX is delighted to welcome Dr Kerry Illston who joins the team of nonclinical safety experts and will be working with Dr Richard Knight. Kerry is an experienced Project Manager with over 25 years’ experience in molecular toxicology, new target identification/validation and nonclinical safety [...]

By |2022-11-22T13:09:36+00:00September 23rd, 2022|Company News, Toxicology, Careers|Comments Off on ApconiX Welcomes Dr Kerry Illston

Queen’s Award Celebration

Queen's Award Celebration On Tuesday the 6th of September Lady Redmond, Lord Lieutenant of Cheshire came to Alderley Park to present ApconiX with the Queen’s Award for Enterprise in recognition of excellence in international trade.  Lady Redmond, accompanied by Sir Philip Redmond, presented the certificate to the directors and co-founders Dr Richard Knight, [...]

By |2022-09-28T11:44:16+01:00September 21st, 2022|Company News|Comments Off on Queen’s Award Celebration

Platelet Function Testing in Target Safety Assessments

Platelet Function Testing in Target Safety Assessments Adverse Findings Adverse findings in non-clinical safety/toxicity testing continue to be a major reason for failure and/or complexity in drug projects. Since primary target-related toxicity plays a role in a significant proportion of these failures, an in-depth assessment of potential adverse consequences [...]

By |2022-09-21T12:16:41+01:00September 7th, 2022|Company News, Target Safety Assessments|Comments Off on Platelet Function Testing in Target Safety Assessments

ApconiX is Co-organising a One Day BTS Discovery Toxicology 2022 Event

ApconiX is Co-organising a One Day BTS Discovery Toxicology 2022 Event Dr Nicholas Coltman and Professor Ruth Roberts are co-organising the Science-led Strategies for Success in Discovery & Development Toxicology on Wednesday 15th June 2022 at the Alderley Park Conference Centre in Cheshire.  ApconiX is co-organising the event with [...]

By |2022-09-21T12:28:13+01:00May 17th, 2022|Toxicology, Events|Comments Off on ApconiX is Co-organising a One Day BTS Discovery Toxicology 2022 Event

ApconiX Is Recruiting a Business Development Assistant

ApconiX Is Recruiting a Business Development Assistant The closing date for this job vacancy has passed.  Please visit our Come and Join Us page for current vacancies.  If you believe you have the skills and experience and would like to become part of our team please send your speculative CV to careers@apconix.com ApconiX [...]

By |2022-09-21T12:28:35+01:00May 12th, 2022|Careers|Comments Off on ApconiX Is Recruiting a Business Development Assistant

DDTSS “Paper of the Year” Award Webinar

DDTSS “Paper of the Year” Award Webinar The Drug Discovery Toxicology Specialty Section (DDTSS) DDTSS is hosting a webinar entitled “Species-specific urothelial toxicity with an anti-HIV noncatalytic site integrase inhibitor (NCINI) is related to unusual pH-dependent physicochemical changes" to present the work that was published in Toxicological Sciences and [...]

By |2022-08-22T14:48:21+01:00May 6th, 2022|Toxicology, Events|Comments Off on DDTSS “Paper of the Year” Award Webinar
Go to Top